Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Genzyme

This article was originally published in The Gray Sheet

Executive Summary

Genzyme: Firm's Genzyme Tissue Repair division receives $10 mil. "for general corporate purposes" from sister division Genzyme General "in exchange for an increase of one million Tissue Repair designated shares," the firm states. The designated shares "are not issued or outstanding" but may be held or sold by the Genzyme board of directors "from time to time for the benefit of Genzyme General without allocating any consideration to Genzyme Tissue Repair," or may be distributed "as a stock dividend to holders of Genzyme General common stock." Parent firm Genzyme retains an option, valid until June 15, 1998, to "allocate an additional $10 mil." from Genzyme General to Genzyme Tissue Repair "in exchange for an increase in Tissue Repair designated shares at the rate of $10 per share," Genzyme says...

You may also be interested in...



UK’s NICE Backs Interim Funding For 14-Day Ambulatory Heart Monitoring Tech

Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.

QUOTED. 1 December. Rob Field.

UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.

Aducanumab Review: Looking For Precedents – Long Ago And Far Afield

The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel